| scholarly article | Q13442814 |
| P50 | author | W. Martin Kast | Q78138546 |
| P2093 | author name string | Diane M Da Silva | |
| Neil L Berinstein | |||
| Andrew W Woodham | |||
| James E Egan | |||
| Paul H Naylor | |||
| P2860 | cites work | Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States | Q22306233 |
| IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking | Q28208563 | ||
| Regulation of interferon-gamma during innate and adaptive immune responses | Q28256001 | ||
| Langerhans cells arise from monocytes in vivo | Q28294423 | ||
| Interleukin-12 and the regulation of innate resistance and adaptive immunity | Q29614602 | ||
| Interferon for the treatment of genital warts: a systematic review | Q33505782 | ||
| Inhibition of Langerhans cell maturation by human papillomavirus type 16: a novel role for the annexin A2 heterotetramer in immune suppression | Q33604135 | ||
| Novel neoadjuvant immunotherapy regimen safety and survival in head and neck squamous cell cancer | Q33772810 | ||
| PGE(2) transiently enhances DC expression of CCR7 but inhibits the ability of DCs to produce CCL19 and attract naive T cells | Q34124931 | ||
| Human papillomavirus virus-like particles do not activate Langerhans cells: a possible immune escape mechanism used by human papillomaviruses | Q34148415 | ||
| Differential uptake and cross-presentation of human papillomavirus virus-like particles by dendritic cells and Langerhans cells | Q34211045 | ||
| Suppression of Langerhans cell activation is conserved amongst human papillomavirus α and β genotypes, but not a µ genotype | Q34408919 | ||
| Human papillomavirus can escape immune recognition through Langerhans cell phosphoinositide 3-kinase activation | Q34420097 | ||
| Local immunosuppression induced by high viral load of human papillomavirus: characterization of cellular phenotypes producing interleukin-10 in cervical neoplastic lesions. | Q34480019 | ||
| IRX-2, a novel immunotherapeutic, enhances functions of human dendritic cells | Q34585798 | ||
| HPV: from infection to cancer | Q34716560 | ||
| Origin, homeostasis and function of Langerhans cells and other langerin-expressing dendritic cells | Q34887778 | ||
| A major role for the minor capsid protein of human papillomavirus type 16 in immune escape | Q35009965 | ||
| T cell targeted immune enhancement yields effective T cell adjuvants | Q35177585 | ||
| IRX-2, a novel biologic, favors the expansion of T effector over T regulatory cells in a human tumor microenvironment model | Q35714195 | ||
| Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. | Q35840539 | ||
| Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model | Q35891225 | ||
| A review of clinical trials of human papillomavirus prophylactic vaccines | Q36259403 | ||
| Langerhans cells from women with cervical precancerous lesions become functionally responsive against human papillomavirus after activation with stabilized Poly-I:C | Q36315857 | ||
| Human papillomavirus-exposed Langerhans cells are activated by stabilized Poly-I:C. | Q36350381 | ||
| Dendritic cells in a mature age. | Q36475977 | ||
| Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles | Q36654802 | ||
| Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis | Q36839249 | ||
| Therapeutic Approaches to Genital Warts | Q36870221 | ||
| Migration of dendritic cell subsets and their precursors. | Q37017615 | ||
| IRX-2, a novel immunotherapeutic, protects human T cells from tumor-induced cell death | Q37040433 | ||
| IRX-2, a novel immunotherapeutic, enhances and protects NK-cell functions in cancer patients | Q37040481 | ||
| Peptide Based Vaccine Approaches for Cancer-A Novel Approach Using a WT-1 Synthetic Long Peptide and the IRX-2 Immunomodulatory Regimen | Q37148167 | ||
| Reversal of human papillomavirus-specific T cell immune suppression through TLR agonist treatment of Langerhans cells exposed to human papillomavirus type 16. | Q37349884 | ||
| Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic | Q37353496 | ||
| Monocyte chemoattractant protein-1 (MCP-1): an overview | Q37481208 | ||
| Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen | Q37634052 | ||
| Epidemiology and burden of HPV infection and related diseases: implications for prevention strategies | Q37941160 | ||
| Global burden of human papillomavirus and related diseases. | Q38064060 | ||
| The origins and functions of dendritic cells and macrophages in the skin | Q38214043 | ||
| Incidence, prevalence, and clearance of type-specific human papillomavirus infections: The Young Women's Health Study | Q38454100 | ||
| Immunologic functions of Ia-bearing epidermal Langerhans cells | Q39515233 | ||
| Immunology of papillomavirus infection. | Q41103016 | ||
| A short course of neoadjuvant IRX-2 induces changes in peripheral blood lymphocyte subsets of patients with head and neck squamous cell carcinoma | Q41893614 | ||
| Transforming growth factor beta1, in the presence of granulocyte/macrophage colony-stimulating factor and interleukin 4, induces differentiation of human peripheral blood monocytes into dendritic Langerhans cells | Q41965708 | ||
| Functional analysis of HPV-like particle-activated Langerhans cells in vitro. | Q42182816 | ||
| Molecular analysis of human papillomavirus virus-like particle activated Langerhans cells in vitro | Q42182822 | ||
| A phase 1 safety study of an IRX-2 regimen in patients with squamous cell carcinoma of the head and neck | Q42663612 | ||
| IRX-2 increases the T cell-specific immune response to protein/peptide vaccines | Q42823674 | ||
| Systemic α-interferon (Wellferon) treatment of genital human papillomavirus (HPV) type 6, 11, 16, and 18 infections: Double-blind, placebo-controlled trial | Q43481406 | ||
| A pilot study of perilymphatic leukocyte cytokine mixture (IRX-2) as neoadjuvant treatment for early stage cervical carcinoma | Q44109241 | ||
| Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014--United States | Q45375225 | ||
| Heterologous papillomavirus virus-like particles and human papillomavirus virus-like particle immune complexes activate human Langerhans cells. | Q45512552 | ||
| Human dendritic cells are activated by chimeric human papillomavirus type-16 virus-like particles and induce epitope-specific human T cell responses in vitro | Q45737453 | ||
| Human papillomavirus type 16 in head and neck carcinogenesis. | Q53357344 | ||
| A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone | Q68815180 | ||
| Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins | Q71616385 | ||
| Double-blind, randomized clinical trial on the effect of interferon-beta in the treatment of condylomata acuminata | Q72130532 | ||
| Management of condylomata acuminata with Alferon N injection, interferon alfa-n3 (human leukocyte derived) | Q72180828 | ||
| Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2 | Q72275233 | ||
| Interleukins and contrasuppression induce immune regression of head and neck cancer | Q72384021 | ||
| Papillomavirus-like particles induce acute activation of dendritic cells | Q73785306 | ||
| Human leukocyte derived interferon-alpha in a hydrophilic gel for the treatment of intravaginal warts in women: a placebo-controlled, double-blind study | Q77750733 | ||
| Human Langerhans cells express a specific TLR profile and differentially respond to viruses and Gram-positive bacteria | Q79370197 | ||
| IRX-2, a novel in vivo immunotherapeutic, induces maturation and activation of human dendritic cells in vitro | Q80713795 | ||
| Measurement of proliferative responses of cultured lymphocytes | Q81831780 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cell biology | Q7141 |
| Papillomavirus | Q1137717 | ||
| P304 | page(s) | 291-301 | |
| P577 | publication date | 2015-12-10 | |
| P1433 | published in | Journal of Interferon and Cytokine Research | Q15754749 |
| P1476 | title | Immunostimulatory Activity of the Cytokine-Based Biologic, IRX-2, on Human Papillomavirus-Exposed Langerhans Cells | |
| P478 | volume | 36 |
| Q37135023 | Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases. |
| Q49591682 | Modulation of antigen presenting cell functions during chronic HPV infection. |
| Q92715593 | Papillomavirus Immune Evasion Strategies Target the Infected Cell and the Local Immune System |
| Q64057061 | Strategies for developing and optimizing cancer vaccines |
| Q55003290 | Viral Modulation of TLRs and Cytokines and the Related Immunotherapies for HPV-Associated Cancers. |
Search more.